The GLP is committed to full transparency. Download and review our 2019 Annual Report

Coronavirus immunotherapy could arrive by early summer. Is ‘record time’ fast enough?

| | March 25, 2020
when to stop treatment
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Blood-plasma-based cures aren’t just the stuff of movies. There’s plenty of science to back the idea that blood products from survivors of viral diseases — containing antibodies primed against the virus — can jump-start an immune response in new patients.

In confronting the Covid-19 pandemic, drug makers instead are racing to produce high-tech derivatives in the form of monoclonal or polyclonal antibodies engineered to home in on pieces of the coronavirus. Scientists view them as likely to be both safer and more targeted, but they have yet to provide a Hollywood ending to any outbreak.

It takes time to engineer and purify these antibodies — and past epidemics have often waned before the drugs were ready. They also present myriad logistical hurdles: They have to be kept cold, for instance, and must be infused into patients rather than swallowed. And they’re expensive.

Related article:  Why esketamine will force doctors to rethink office visits for depressed patients

Now two companies say they hope to have treatments for Covid-19 ready in record time.

Japan-based Takeda Pharmaceutical says its unit devoted to plasma-derived therapies could have a product ready for quick approval to fight the coronavirus. New York-based biotech Regeneron has said it can be ready to test hundreds of potential antibodies in Covid-19 patients by early summer.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend